The Transmission of Artemisinin Resistant Parasites Before and After Conventional Artemisinin-combination Therapy
- Conditions
- Falciparum; Malaria
- Interventions
- Registration Number
- NCT06347471
- Lead Sponsor
- Infectious Diseases Research Collaboration, Uganda
- Brief Summary
A prospective study will be carried out in an area where parasites with reduced sensitivity to malaria drugs (artemisinins) have recently emerged. The study will recruit participants from patients who attend the clinic with uncomplicated malaria and asymptomatically infected individuals. Participants are treated with conventional artemisinin-combination therapies (ACT) as part of standard clinical care. From this population, we will select P. falciparum gametocyte carriers.
Before, during and after ACT treatment, the transmission potential of artemisinin resistant and wild type infections will be assessed by microscopy, molecular methods, parasite culture and mosquito feeding assays. Parasite clearance will be determined in the first days (d0-3) after treatment.
The study population will consist of passively recruited patients with uncomplicated P. falciparum malaria and asymptomatically infected individuals who are microscopy positive for gametocytes. Participants will be treated with conventional therapies for uncomplicated malaria without randomization: artemether-lumefantrine (AL) or dihydroartemisinin-piperaquine (DHA-PPQ). All doses are supervised. Parasite clearance is assessed ex vivo by ring-stage survival assays and by daily slides during the first days of treatment.
Gametocyte carriage and gametocyte commitment/production will be determined for resistant and wild type infections before, during and after treatment. In addition, venous blood will be collected at three timepoints to assess transmission to mosquitoes before (d0), during (d2) and after treatment (d7). The total duration of participation will be 7 days, the primary endpoint will be the reduction in mosquito infection rates at d2 (artemether-lumefantrine) or d7 (dihydroartemisinin-piperaquine) compared to pre-treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 120
- age ≥2 years
- blood smear positive for P. falciparum gametocytes
- mono-infection with P. falciparum confirmed by positive blood smear;
- parasitaemia of >100 P. falciparum asexual forms/µL;
- ability to swallow oral medication;
- ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule;
- informed consent from parent or guardian;
- haemoglobin ≥ 7.0 g/dl for children below 10 years of age or ≥8.0g/dL for older individuals
- presence of general danger signs;
- mixed or mono-infection with another Plasmodium species detected by microscopy;
- presence of severe malnutrition defined as a very low weight for height (below -3z scores of the median WHO growth standards), by visible severe wasting, or by the presence of nutritional oedema.
- presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);
- history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description artemether-lumefantrine Artemether-lumefantrine artemether-lumefantrine according to manufacturer instructions dihydroartemisinin-piperaquine Dihydroartemisinin-Piperaquine dihydroartemisinin-piperaquine according to manufacturer instructions
- Primary Outcome Measures
Name Time Method Mean within person percent change (presented as percent reduction) in mosquito infection rate in infectious individuals from baseline. day 2 vs day 0 (AL arm) and day 7 vs day 0 (DP arm) Mean within person percent change (presented as percent reduction) in mosquito infection rate in infectious individuals from baseline (day 0, pre-treatment) to day 2 post treatment in the AL and day 7 post-treatment in the DHA-PPQ arm. Infectivity is assessed by mosquito membrane feeding assays; percent reduction is calculated separately for ΔPfK13 vs wild type infections.
- Secondary Outcome Measures
Name Time Method Mean within person percent change (presented as percent reduction) in mosquito infection rate from baseline days 0, 2, 7 Mean within person percent change (presented as percent reduction) in mosquito infection rate from baseline to all feeding time-points. Infectivity is assessed by mosquito membrane feeding assays; comparisons are performed within treatment arms for ΔPfK13 vs wild type infections.
Mean oocyst intensity (in all/all infected mosquitoes) days 0, 2, 7 Mean oocyst intensity (in all/all infected mosquitoes) will be assessed at all feeding time-points; comparisons are performed within treatment arms for ΔPfK13 vs wild type infections
Male and female gametocyte sex ratio (proportion male) days 0, 1, 2, 3, 7 Male and female gametocyte sex ratio (proportion male) at all time-points, determined by molecular assays; comparisons are performed within treatment arms for ΔPfK13 vs wild type infections.
Gametocyte circulation time days 0, 1, 2, 3, 7 Gametocyte circulation time (cumulative), determined by microscopy or molecular assays, compared between treatment arms and between ΔPfK13 vs wild type infections
Gametocyte area under the curve days 0, 1, 2, 3, 7 Gametocyte area under the curve (cumulative), determined by microscopy or molecular assays, compared between treatment arms, and between ΔPfK13 vs wild type infections
Asexual parasite prevalence days 0, 1, 2, 3, 7 Asexual parasite prevalence at all time-points, determined by microscopy or molecular assays, with comparison within treatment arms, between arms, and between ΔPfK13 vs wild type infections
Asexual parasite density days 0, 1, 2, 3, 7 Asexual parasite density at all time-points, determined by microscopy or molecular assays, with comparison within treatment arms, between arms, and between ΔPfK13 vs wild type infections
Total parasite prevalence days 0, 1, 2, 3, 7 Total parasite prevalence at all time-points, determined by microscopy or molecular assays, with comparison within treatment arms, between arms, and between ΔPfK13 vs wild type infections
Total parasite density days 0, 1, 2, 3, 7 Total parasite density at all time-points, determined by microscopy or molecular assays, with comparison within treatment arms, between arms, and between ΔPfK13 vs wild type infections
The density of ΔPfK13 vs wild type genotypes days 0, 1, 2, 3, 7 The density of ΔPfK13 vs wild type genotypes in peripheral blood, the asexual parasite fraction and gametocyte fraction before and after initiation of treatment. The relative abundance of ΔPfK13 genotypes will be compared between pre- and post-treatment timepoints
The density of ΔPfK13 vs wild type genotypes in oocysts and sporozoites in mosquitoes that become infected before and after initiation of treatment days 0, 2, 7 The density of ΔPfK13 vs wild type genotypes in oocysts and sporozoites in mosquitoes that become infected before and after initiation of treatment. The relative abundance of ΔPfK13 genotypes will be compared between pre- and post-treatment timepoints
Mean within person percent change (presented as percent reduction) in mosquito infection rate from baseline after gametocyte enrichment days 0, 2, 7 Mean within person percent change (presented as percent reduction) in mosquito infection rate from baseline to all feeding time-points. Infectivity is assessed by mosquito membrane feeding assays after gametocyte enrichment; comparisons are performed within treatment arms for ΔPfK13 vs wild type infections.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (2)
Dr. Ambrosoli Memorial Hospital
🇺🇬Kalongo, Agago district, Uganda
Patongo Health Facility IV
🇺🇬Patongo, Agago district, Uganda